- Home
- ACAD vs GNW Comparison
ACAD vs GNW Comparison
Compare ACAD & GNW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- GNW
- Stock Information
- Founded
- ACAD 1993
- GNW 1871
- Country
- ACAD United States
- GNW United States
- Employees
- ACAD N/A
- GNW N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- GNW Life Insurance
- Sector
- ACAD Health Care
- GNW Finance
- Exchange
- ACAD Nasdaq
- GNW Nasdaq
- Market Cap
- ACAD 4.3B
- GNW 3.5B
- IPO Year
- ACAD 2004
- GNW 2004
- Fundamental
- Price
- ACAD $23.61
- GNW $8.80
- Analyst Decision
- ACAD Buy
- GNW Buy
- Analyst Count
- ACAD 21
- GNW 1
- Target Price
- ACAD $29.30
- GNW $9.50
- AVG Volume (30 Days)
- ACAD 1.9M
- GNW 3.7M
- Earning Date
- ACAD 11-05-2025
- GNW 11-05-2025
- Dividend Yield
- ACAD N/A
- GNW N/A
- EPS Growth
- ACAD 615.00
- GNW 512.33
- EPS
- ACAD 1.33
- GNW 0.44
- Revenue
- ACAD $1,018,885,000.00
- GNW $7,261,000,000.00
- Revenue This Year
- ACAD $14.01
- GNW N/A
- Revenue Next Year
- ACAD $11.72
- GNW N/A
- P/E Ratio
- ACAD $17.82
- GNW $20.10
- Revenue Growth
- ACAD 14.41
- GNW N/A
- 52 Week Low
- ACAD $13.40
- GNW $5.99
- 52 Week High
- ACAD $26.65
- GNW $8.85
- Technical
- Relative Strength Index (RSI)
- ACAD 39.78
- GNW 64.89
- Support Level
- ACAD $23.70
- GNW $8.46
- Resistance Level
- ACAD $25.90
- GNW $8.73
- Average True Range (ATR)
- ACAD 0.74
- GNW 0.15
- MACD
- ACAD -0.33
- GNW -0.01
- Stochastic Oscillator
- ACAD 8.16
- GNW 88.04
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About GNW Genworth Financial Inc
Genworth Financial Inc is a diversified insurance holding company that provides various mortgage and life insurance products. The company has three main operating business segments: Enact, Life and Annuities segment and Long-Term Care Insurance. The company's product portfolio includes various financial products such as traditional life insurance, mortgage insurance, fixed annuities, and variable annuities. Majority of the revenue is generated by the Enact segment. The company earns maximum of its revenue in the United States.